Danish drugmaker Novo Nordisk (NOVOb.CO) has partnered with Hims & Hers Well being’s (HIMS.N) to promote its standard weight reduction drug by a bundled providing on the telehealth firm’s platform, the 2 firms mentioned on Tuesday.
Prospects will get entry to the choices of all dose strengths of Wegovy and a membership at a worth beginning at $599 per thirty days, Hims mentioned.
The providing is obtainable this week on the Hims & Hers platform, it added.
The businesses are constructing a longer-term roadmap of bundled choices that may have very distinctive worth and pricing to shoppers that hopefully we’re capable of share within the coming quarters, Hims CEO Andrew Dudum mentioned.
Earlier this month, Hims mentioned it plans to promote Eli Lilly’s (LLY.N) Zepbound on its platform.
Whereas Novo’s Wegovy and Lilly’s rival drug, Zepbound, had been briefly provide, a number of telehealth firms had been allowed to promote cheaper copies of the remedies. The branded medication have since been faraway from the US Meals and Drug Administration’s scarcity listing, doubtlessly curbing bulk compounding.
The corporate will proceed to supply personalised compounded variations of semaglutide on its platform, Dudum added.
Semaglutide is the energetic ingredient in Novo’s Wegovy.
By Sriparna Roy; Edited by Anil D’Silva
Be taught extra:
Why the Weight problems Drug Revolution Is a Work in Progress
GLP-1 weight-loss medication like Wegovy and Zepbound are revolutionising weight problems remedy and producing billions for his or her makers, however challenges together with excessive prices, insurance coverage protection points, drug shortages, and competitors from copycats might affect their widespread success.
